# US 2025/0152592 A1 · Pharmaceutical composition comprising allopurinol, febuxostat or pharmaceutically acceptable salt thereof for prevention or treatment of chronic kidney disease in subject having high serum uric acid concentration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152592 A1
- Document ID: US20250152592A1
- Status: Published application
- Kind: A1
- Application number: 18/836,184
- Filed: 2023-01-30
- Published: 2025-05-15
- Earliest claimed: 2022-02-07
- Assignees: Indream Healthcare Inc.
- Applicants: Indream Healthcare Inc.
- Inventors: Byeong Zu GHANG
- Web page: https://patentgrep.com/patent/US20250152592A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/426: 1,3-Thiazoles
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of allopurinol, febuxostat or a pharmaceutically acceptable salt thereof for the prevention or treatment of chronic kidney disease in a subject having a high serum uric acid concentration, wherein when administered to a subject having a serum uric acid level of 6 mg/dl or more, the pharmaceutical composition reduces the subject's serum uric acid level to less than 6 mg/dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitors, and thus can effectively treat or prevent chronic kidney disease by being administered to a selected subject.

## Claims

### Claim 1

A method for treating chronic kidney disease comprising: administering a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient, to a subject having a serum uric acid concentration of 6 mg/dl or more, wherein said administering decreases the serum uric acid concentration of the subject to less than 6 mg/dl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has a blood glucose level of 126 mg/dl or more, a diastolic blood pressure of 80 mmHg or lower, or a systolic blood pressure of 130 mmHg or lower.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject has the blood glucose level of 126 mg/dl or more.

### Claim 4 (depends on 2)

The method of claim 2, wherein the subject has the diastolic blood pressure of 80 mmHg or lower and the systolic blood pressure of 130 mmHg or lower.

### Claim 5 (depends on 1)

The method of claim 1, wherein the active ingredient is the allopurinol or the pharmaceutically acceptable salt thereof, and the subject has no congestive cardiac failure.

### Claim 6 (depends on 1)

The method of claim 1, wherein the active ingredient is the febuxostat or the pharmaceutically acceptable salt thereof, and the subject has the serum uric acid concentration of 8 mg/dL or more.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has the serum uric acid concentration of 7 mg/dl or more.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has hyperuricacidemia or gout.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has gout.

### Claim 10 (depends on 9)

The method of claim 9, wherein the active ingredient is the febuxostat or the pharmaceutically acceptable salt thereof, and wherein the gout has lasted 10 years or more.

### Claim 11 (depends on 1)

The method of claim 1, wherein the active ingredient is the allopurinol or the pharmaceutically acceptable salt thereof, and a dosage of the active ingredient is administered at a dosage of 100 mg to 600 mg per day based on an amount of the allopurinol.

### Claim 12 (depends on 1)

The method of claim 1, wherein the active ingredient is the febuxostat or the pharmaceutically acceptable salt thereof, and a dosage of the active ingredient is administered at a dosage of 20 mg to 120 mg per day based on an amount of the febuxostat.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has an estimated glomerular filtration rate (eGFR) of 45 ml/min/1.73 m2 or more.

### Claim 14 (depends on 1)

The method of claim 1,
wherein the active ingredient is the allopurinol or the pharmaceutically acceptable salt thereof,
wherein the active ingredient is administered to the subject having the eGFR of 60 ml/min/1.73 m2 or more at a dose of 300 mg per day based on an amount of the allopurinol, and if the serum uric acid concentration of the subject is not decreased to less than 6 mg/dl at one month after the administration, the active ingredient is administered at a dose of 600 mg per day based on the amount of the allopurinol, and
wherein the active ingredient is administered to the subject having the eGFR of 30 ml/min/1.73 m2 or more and less than 60 ml/min/1.73 m2 at a dose of 200 mg per day based on the amount of the allopurinol, and if the serum uric acid concentration of the subject is not decreased to less than 6 mg/dl at one month after the administration, the active ingredient is administered at a dose which increased in increments of 100 mg per month up to a maximum of 400 mg per day based on the amount of the allopurinol.

### Claim 15 (depends on 1)

The method of claim 1,
wherein the active ingredient is the febuxostat or the pharmaceutically acceptable salt thereof, and
the active ingredient is administered at a dose of 40 mg per day based on an amount of the febuxostat, and if the serum uric acid concentration of the subject is not decreased to less than 6 mg/dl at 2 weeks after the administration, the active ingredient is administered at a dose of 80 mg per day based on the amount of the febuxostat.
